---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-21-012080"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:17:27.019614+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Zomedica Q3 net loss $6.3M; revenue minimal from TRUFORMA launch; cash $271.4M

## Summary
- Net loss of $6.3M ($0.01/share) vs $5.0M loss in Q3 2020; nine-month loss $15.1M.
- Revenue from TRUFORMA products was $22,514; commercial launch began March 2021.
- Cash and equivalents $271.4M at Sept 30, 2021; pro forma after PulseVet acquisition ~$199.5M.
- SG&A expense rose 166% to $6.1M, driven by share-based compensation and PulseVet deal costs.
- R&D expense fell 89% to $0.3M as initial TRUFORMA assays completed; development shifts to commercialization.

## SEC filing metadata
- accession: 0001654954-21-012080
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495421012080/0001654954-21-012080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495421012080/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-21-012080
- JSON: https://secwatch.observer/filing/0001654954-21-012080.json
- Plain text: https://secwatch.observer/filing/0001654954-21-012080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.